Bristol-Myers Squibb Company (BMY): Price and Financial Metrics
BMY Stock Summary
- With a market capitalization of $138,080,483,679, Bristol Myers Squibb Co has a greater market value than 98.42% of US stocks.
- BMY's went public 35.19 years ago, making it older than 92.77% of listed US stocks we're tracking.
- In terms of volatility of its share price, BMY is more volatile than merely 0.6% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to Bristol Myers Squibb Co are SNY, RTX, DE, AMGN, and AZN.
- BMY's SEC filings can be seen here. And to visit Bristol Myers Squibb Co's official web site, go to www.bms.com.
BMY Stock Price Chart Interactive Chart >
BMY Price/Volume Stats
|Current price||$61.27||52-week high||$67.16|
|Prev. close||$61.63||52-week low||$45.76|
|Day high||$62.18||Avg. volume||12,951,763|
|50-day MA||$62.27||Dividend yield||3.18%|
|200-day MA||$60.92||Market Cap||137.27B|
Bristol-Myers Squibb Company (BMY) Company Bio
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular. The company was founded in 1887 and is based in New York, New York.
BMY Latest News Stream
|Loading, please wait...|
BMY Latest Social Stream
View Full BMY Social Stream
Latest BMY News From Around the Web
Below are the latest news stories about Bristol Myers Squibb Co that investors may wish to consider to help them evaluate BMY as an investment opportunity.
Investment Thesis The promising clinical results of CRISPR Therapeutics' (CRSP) pipeline combined with their blockbuster potential provide an attractive investment proposition for investors wishing to establish a biotech position. CRSP is one of the few companies holding a patent to use CRISPR. This disruptive gene-editing technology helped its discoverers win...
Changes to top holdings Citigroup and GE
Bristol Myers Squibb Announces Dividend
Growth stocks increase their sales by a double-digit percentage, are concerned with gobbling up market share, and aren't too focused on generating a profit. Meanwhile, value stocks are companies that have forward price-to-earnings multiples or price-to-earnings-growth ratios (PEG ratio) below the average of their industry or the broader market.
Bristol-Myers Squibb: Undervalued Dividend Contender, Offering Income, Dividend Growth, And Capital Appreciation
Investment Thesis Bristol-Myers Squibb (BMY) is a biopharmaceutical company whose focus is on discovering, developing, and delivering transformational medicines for patients facing serious diseases in areas where they believe that there is an opportunity to make a meaningful difference: oncology (both solid tumors and hematology), immunology, cardiovascular and fibrosis. During...
BMY Price Returns
|Ex-Dividend Date||Type||Payout Amount||Change|
|Loading, please wait...|
Continue Researching BMYHere are a few links from around the web to help you further your research on Bristol Myers Squibb Co's stock as an investment opportunity:
Bristol Myers Squibb Co (BMY) Stock Price | Nasdaq
Bristol Myers Squibb Co (BMY) Stock Quote, History and News - Yahoo Finance
Bristol Myers Squibb Co (BMY) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!